Samuel Bjork is a Partner at Digitalis Ventures, where he leads the firm’s life sciences practice.
He has served as a director or observer on the boards of multiple companies, including Elemental Machines, EpiBiologics, Good Therapeutics (acquired by Roche), Nuvig Therapeutics, PetMedix (acquired by Zoetis), T-Therapeutics, and Terray Therapeutics, among others. Prior to Digitalis, Samuel was a member of the healthcare and clean energy practices at the Boston Consulting Group. He received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University.